Who are R-CHOEP 14 with 12x Rituximab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Arm D: FOLFIRI or FOLFOX plus CETUXIMAB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r-choep-14-with-12x-rituximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

R-CHOEP 14 with 12x Rituximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

R-CHOEP 14 with 12x Rituximab (R-CHOEP 14 with 12x Rituximab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with monoclonal antibody. Area: Oncology.

phase 3 Chemotherapy combination with monoclonal antibody CD20 (rituximab component); DNA/topoisomerase II (chemotherapy components) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

R-CHOEP 14 with 12x Rituximab (R-CHOEP 14 with 12x Rituximab) — German High-Grade Non-Hodgkin's Lymphoma Study Group. R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
R-CHOEP 14 with 12x Rituximab TARGET	R-CHOEP 14 with 12x Rituximab	German High-Grade Non-Hodgkin's Lymphoma Study Group	phase 3	Chemotherapy combination with monoclonal antibody	CD20 (rituximab component); DNA/topoisomerase II (chemotherapy components)
Arm D: FOLFIRI or FOLFOX plus CETUXIMAB	Arm D: FOLFIRI or FOLFOX plus CETUXIMAB	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	phase 3	Chemotherapy combination with monoclonal antibody	EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with monoclonal antibody class)

German High-Grade Non-Hodgkin's Lymphoma Study Group · 1 drug in this class
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). R-CHOEP 14 with 12x Rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/r-choep-14-with-12x-rituximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab